Using cancer phenotype sex-specificity to enable unbiased penetrance estimation of SMARCA4 pathogenic variants for small cell carcinoma of the ovary, hypercalcemic type (SCCOHT).
pubmed.ncbi.nlm.nih.gov shows its articles on its own site.
Read the article on pubmed.ncbi.nlm.nih.gov ↗Article · Nov 2026 · 1 min read
In brief
In brief
This study addresses the challenge of estimating cancer penetrance for SMARCA4 germline pathogenic variants in small cell carcinoma of the ovary, hypercalcemic type (SCCOHT), a rare aggressive cancer affecting young women. By leveraging the sex-specific nature of SCCOHT, researchers developed an unbiased methodology to quantify risk, informing decisions about prophylactic bilateral oophorectomy.
Written by the GCMD Library team from the article.
Statements in this article
Small cell carcinoma of the ovary, hypercalcemic type has a mean age of onset of 24 years.
Nearly all cases of SCCOHT are associated with somatic or germline pathogenic variants in SMARCA4.
Early bilateral oophorectomy is recommended for unaffected females with a SMARCA4 germline pathogenic variant.
The penetrance of SMARCA4 germline pathogenic variants for SCCOHT is highly uncertain.